Explore Our Trials
Gateway for Cancer Research is one of the only nonprofits that exclusively funds innovative Phase I and Phase II cancer clinical trials for patients of all ages, regardless of cancer type. At the forefront of research and discovery, these early-phase trials are the first step in evaluating new cancer drugs, treatments, and therapies.
Results 51-58 of 58
Breast Cancer
Identification of Predictive Protein Pathway Activation Biomarkers for Neoadjuvant Breast Cancer Therapy Treatment from the ISPY2 TRIAL
Identification of Predictive Protein Pathway Activation Biomarkers for Neoadjuvant Breast Cancer Therapy Treatment from the ISPY2 TRIAL Summary: Over 200,000 women are diagnosed with breast cancer annually in the United States and breast cancer is responsible for approximately 45,000 deaths annually in the U.S. While those diagnosed with early-stage breast cancer have excellent outcomes, 10-20% […]
Emanuel Petricoin, PhD
George Mason University
Breast Cancer
Copper depletion as a therapeutic strategy to prevent metastases in triple negative breast cancer: Unraveling the mechanisms behind the effect of copper depletion on the tumor and tumor microenvironment
Copper depletion as a therapeutic strategy to prevent metastases in triple negative breast cancer: Unraveling the mechanisms behind the effect of copper depletion on the tumor and tumor microenvironment Summary: Triple-negative breast cancer (TNBC) is an aggressive cancer that accounts for 15-20% of all breast cancer cases; however, it is responsible for 50% of metastasis-related […]
Linda Vahdat, MD, MBA
Dartmouth
Pediatric Sarcoma
Phase 2 Study of Regorafenib in Combination with Immune Checkpoint Inhibitor Nivolumab in Patients with Refractory or Recurrent Osteosarcoma
Phase 2 Study of Regorafenib in Combination with Immune Checkpoint Inhibitor Nivolumab in Patients with Refractory or Recurrent Osteosarcoma Summary: Osteosarcoma is the most common malignant bone tumor in children and young adults, with a peak incidence between 13 and 16 years of age. The mainstay of treatment is intensive multi-agent cytotoxic chemotherapy but despite […]
Fariba Navid, MD
Children's Hospital Los Angeles
Pancreatic Cancer
A Phase 1b/2 Trial of Immunotherapy with Avelumab and Pepinemab as Second Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma
A Phase 1b/2 Trial of Immunotherapy with Avelumab and Pepinemab as Second Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma Summary: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers and an almost uniformly fatal malignancy. Treatment outcomes remain dismal with a 5-year survival of 9%. The incidence of PDAC is increasing and […]
David Linehan, MD
University of Rochester
Pediatric Rare Cancer
Phase 2 study of nivolumab and ipilimumab in children and young adults with relapsed or refractory INI1-negative cancers
Phase 2 study of nivolumab and ipilimumab in children and young adults with relapsed or refractory INI1-negative cancers Summary: INI1 is a tumor suppressor gene and several aggressive pediatric tumor types are characterized by INI1 negativity, including rhabdoid tumors, epithelioid sarcoma, and chordoma. These cancers represent a portion of rare tumor diagnoses and each are […]
Suzanne Forrest, MD
Dana-Farber Cancer Institute
Live/Bile Duct
Telemedicine for FGFR focused diagnostics & novel cholangio therapies
Telemedicine for FGFR focused diagnostics & novel cholangio therapies Summary: Cholangiocarcinoma is a rare and aggressive liver cancer affecting the bile duct. Patients with cholangiocarcinoma can benefit from clinical and genetics expertise found at university-based cancer centers. However, most patients cannot travel long distances and pay expensive out-of-pocket costs for this expert level of care. […]
Sameek Roychowdhury, MD, PhD
The Ohio State University
Lung Cancer
Predictive biomarkers for pneumonitis after chemoradiotherapy and immunotherapy in Patients With Non-small Cell Lung Cancer
Predictive biomarkers for pneumonitis after chemoradiotherapy and immunotherapy in Patients With Non-small Cell Lung Cancer Summary: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by producing durable responses. For example, approximately up to 20% of patients with metastatic non-small cell lung cancer (NSCLC) have durable clinical responses. However, this is not without toxicities. Immune-related adverse […]
Ajay Sheshadri, MD, MSCI
MD Anderson Cancer Center
Pediatric Blood Cancer
Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33 CAR T) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia
Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33 CAR T) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia Summary: While a first remission is possible for pediatrics patients with acute myeloid leukemia (AML), only 60% will remain in long-term remission despite intensive therapy and allogeneic stem cell transplant (stem cell transplant from a donor). […]
Steven Devine, MD
Be The Match Foundation
